Innoviva (INVA) Retained Earnings (2010 - 2026)
Innoviva (INVA) posted Retained Earnings of $456.0 million for Q1 2026, up 69.27% on a QoQ basis from $269.4 million in Q4 2025, and up 1042.44% year-over-year from $39.9 million in Q1 2025.
Innoviva (INVA) Retained Earnings (2010 - 2026) Analysis & Trends
Innoviva's Retained Earnings history runs 17 years deep, the most recent figure standing at $456.0 million for Q1 2026.
- Quarterly Retained Earnings rose 1042.44% year-over-year to $456.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $456.0 million (up 1042.44% YoY) and the FY2025 annual result came in at $269.4 million, up 15089.87% from the prior year.
- Retained Earnings was $456.0 million for Q1 2026 at Innoviva, up from $269.4 million in the prior quarter.
- Across five years, Retained Earnings topped out at $456.0 million in Q1 2026 and bottomed at -$204.9 million in Q4 2022.
- A 5-year average of -$2.0 million and a median of -$23.3 million in 2024 frame the typical range for Retained Earnings.
- Peak annual rise in Retained Earnings reached 15089.87% in 2025, while the deepest fall reached 526.53% in 2025.
- Innoviva's Retained Earnings stood at -$204.9 million in 2022, then surged by 87.71% to -$25.2 million in 2023, then surged by 92.87% to -$1.8 million in 2024, then surged by 15089.87% to $269.4 million in 2025, then surged by 69.27% to $456.0 million in 2026.
- Business Quant data shows INVA's Retained Earnings at $456.0 million in Q1 2026, $269.4 million in Q4 2025, and $105.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Innoviva | 1.57 Bn | 969.11 Mn | 75.83 Mn | 455.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 455.96 Mn |
| Dec 31, 2025 | 269.37 Mn |
| Sep 30, 2025 | 105.22 Mn |
| Jun 30, 2025 | 15.31 Mn |
| Mar 31, 2025 | -48.38 Mn |
| Dec 31, 2024 | -1.80 Mn |
| Sep 30, 2024 | -22.13 Mn |
| Jun 30, 2024 | -23.34 Mn |
| Mar 31, 2024 | 11.34 Mn |
| Dec 31, 2023 | -25.19 Mn |
| Sep 30, 2023 | -86.72 Mn |
| Jun 30, 2023 | -168.77 Mn |
| Mar 31, 2023 | -170.05 Mn |
| Dec 31, 2022 | -204.91 Mn |
| Sep 30, 2022 | -136.60 Mn |
| Dec 31, 2021 | -456.15 Mn |
| Sep 30, 2021 | -466.49 Mn |
| Jun 30, 2021 | -538.93 Mn |
| Mar 31, 2021 | -627.88 Mn |
| Dec 31, 2020 | -722.00 Mn |